R&D Programme
B-Lite ™ Research
Exploring how specific light wavelengths interact with human appetite signalling — the same biological pathways that GLP-1 drugs like Ozempic™ and Wegovy™ target. Using light instead of pharmaceuticals.
The question
Can light influence hunger?
GLP-1 receptor agonists have transformed weight management. The global market for these drugs is projected to reach $150 billion by the early 2030s. But they come with side effects, high costs, and supply constraints.
We are researching whether specific wavelengths of light — delivered through a wearable device — can influence the same hunger-signalling pathways. Non-invasive, drug-free, and based on the established science of photobiomodulation.
This is a research programme, not a consumer product. We are pursuing funded clinical work to answer this question properly.
Progress
Further along than you might expect
Patent
UK patent application drafted and submitted. Covers the core mechanism of light-based appetite signalling.
Hardware
Wearable prototype developed. Purpose-built for targeted wavelength delivery to specific body areas.
Software
Control software developed for precise wavelength management, session timing, and data collection.
Skin interface
Custom skin interface developed to optimise light delivery and ensure consistent contact with the body.
The science
Built on photobiomodulation
Photobiomodulation — the use of specific light wavelengths to trigger biological responses in cells — is backed by over 10,000 peer-reviewed studies. It is established science, not speculation.
Our research extends this established foundation into a new application: whether the same photonic principles that drive cellular energy production, inflammation response, and tissue recovery can be applied to appetite regulation.
Our advisory board is led by Prof. Michael Hamblin, one of the world's foremost authorities on photobiomodulation, with over 600 peer-reviewed publications.
Next steps
From research to evidence
We are actively pursuing UK grant funding to move from prototype to clinical evidence. Our targets include Innovate UK, UKRI, Horizon Europe, and other relevant funding bodies.
Most grant applicants start with an idea. We start with a patent, a working prototype, developed software, and a custom skin interface. That puts us ahead of the typical application.
If you're a grant specialist, researcher, or funding body interested in photobiomodulation research — we'd like to hear from you.